Sensible Biotechnologies Raises $47 Million With In-Q-Tel Backing

Sensible Biotechnologies has secured $47 million in financing, combining a Series A round backed by the CIA's venture arm In-Q-Tel with up to $20 million in non-dilutive funding from the Government of Slovakia and the European Union. The company did not disclose the equity portion's size or its valuation.

The Slovak startup will use the capital to scale VECTOR, its integrated platform for designing and manufacturing naturally modified mRNA. Funding will also support AI-enabled mRNA design, automated high-throughput screening and clinical-grade manufacturing capabilities.

Who is investing?

New investors OTB Ventures and In-Q-Tel led the Series A. Existing backers Recode Ventures, Isomer Capital, Y Combinator, Backed VC, Kaya VC, Civilization Ventures and BlueYard Capital also participated.

Individual investors include the family office of BioNTech co-founder Christoph Huber and Tim Garnett, former chief medical officer of Eli Lilly.

The financing reshapes the board. Vishal Gulati, managing partner at Recode Ventures, and Joel Schoppig, partner at Oxford Science Enterprises, will join CEO and co-founder Miroslav "Miro" Gasparek and co-founder and Chief Scientific Officer Marian Kupculak as directors.

Why use cells instead of chemistry?

Conventional mRNA production relies on chemical synthesis, which Sensible argues suffers from cost, scalability and supply-chain constraints — barriers that bite hardest in applications requiring high or repeated doses. Sensible instead engineers living cells to produce the mRNA.

"mRNA transformed vaccines, but we believe its greatest potential lies in therapeutics," Gasparek said. "We are taking a fundamentally different approach, using living cells to produce naturally modified mRNA while reducing the cost and supply-chain constraints of conventional production."

The VECTOR platform combines computational and AI-enabled sequence optimization, high-throughput screening and proprietary engineered eukaryotic cells. Its PromPT technology captures and protects mRNA inside cells before purification.

What do the data show?

According to the company, the cell-based process produces naturally modified mRNA with lower immunogenicity and high protein expression while avoiding double-stranded RNA contamination, a common impurity in synthetic production that can trigger unwanted immune responses.

In external evaluations cited by Sensible, its cell-produced mRNA showed no detectable double-stranded RNA contamination, reduced cytokine activation and higher protein expression compared with synthetic mRNA in human immune-cell assays. Those findings remain preclinical platform results, not evidence of clinical efficacy in patients.

Research on Sensible's cell-based circular RNA manufacturing has been published in Nature Biotechnology and Cell Chemical Biology.

What markets is Sensible chasing?

The commercial target extends well beyond vaccines. Sensible points to cancer treatments, genetic medicines, protein replacement therapies, antibodies and cell therapies. Investors highlight in vivo CAR-T therapies, gene editing and cancer immunotherapy as potential applications.

Manufacturing economics sit at the center of the thesis. Integrating design and production into one platform could cut dependence on the specialized raw materials that conventional manufacturing demands — critical for therapeutics requiring larger or repeated doses.

The company is already moving toward commercial scale. It is working with Sartorius to scale its cell-based technology toward clinical-grade mRNA production, alongside additional technology partnerships.

What does the public money signal?

The non-dilutive component gives Sensible significant public-sector backing as it builds its platform in Europe. Slovak Health Minister Kamil Šaško described the funding as an investment in Europe's ability to participate in the next generation of biotechnology and healthcare innovation.

Schoppig said connecting computational drug design directly with biological production could let Sensible address both mRNA performance and manufacturing economics. He said the financing will help move the company toward clinical-grade production while expanding pharmaceutical partnerships.

With $47 million in hand, Sensible is now shifting from platform development toward manufacturing scale and pharma collaboration — betting that cell-produced, naturally modified mRNA can carry the technology beyond vaccines and into therapeutics where cost, purity and repeated dosing decide winners.